GSK’s Anoro Ellipta beats BI’s Spiolto Respimat in COPD trial
GlaxoSmithKline and Innoviva say their combination lung therapy Anoro Ellipta has come out on top in a trial pitting its effectiveness in improving lung function against that of Boehringer Ingelheim’s Spiolto Respimat.
Read More
